When used in combination, ISOQ and ZAF achieved cooperative enzymatic inhibition in vitro and elicited superior antitumor efficacy in vivo, reducing tumor volume and suppressing tissue factor, VEGF, TMEM176B, and PD‐L1 more effectively than high‐dose monotherapy. The gene discussed is VEGFA; the disease is neoplasm.